Post-acute metabolic sequelae of SARS-CoV-2 infection in nonhuman primates
非人灵长类动物感染 SARS-CoV-2 后急性代谢后遗症
基本信息
- 批准号:10554898
- 负责人:
- 金额:$ 128.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-31 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcuteAddressAdipocytesAdipose tissueAdultAffectAntibody TherapyAntigensAttenuatedAutopsyB-LymphocytesBiopsyBronchoalveolar LavageC-PeptideCOVID-19COVID-19 impactCOVID-19 pandemicCOVID-19 patientCOVID-19 severityCOVID-19 survivorsCardiovascular DiseasesCellsChronicClinical ResearchCoronavirusDataDevelopmentDiabetes MellitusDyslipidemiasEndocrineExhibitsFunctional disorderFutureGlucoseGlucose tolerance testGlycosylated hemoglobin AHIVHIV Envelope Protein gp120HealthHeterogeneityHumanHyperinsulinismHypertensionImmuneInfectionInflammationInsulinInsulin ResistanceInsulin-Dependent Diabetes MellitusInterventionIntestinesIslet CellIslets of LangerhansLightLipidsLiverLung diseasesMacaca mulattaMetabolicMetabolic DiseasesMetabolic dysfunctionModelingMonitorMorbidity - disease rateNon-Insulin-Dependent Diabetes MellitusNucleic AcidsObesityOralPathologyPeripheralPhasePopulationPost-Acute Sequelae of SARS-CoV-2 InfectionPre-Clinical ModelPrediabetes syndromeProcessProteinsPublic HealthPulmonary PathologyReportingRiskSARS-CoV-2 B.1.617.2SARS-CoV-2 infectionSARS-CoV-2 variantSamplingTherapeuticTherapeutic AgentsThinnessTimeTissue SampleTissuesToxic effectTranscriptTreatment EfficacyVaccine TherapyVaccinesViralViral Load resultViral ProteinsViral reservoirViremiaVirus LatencyVirus ReplicationVirus Sheddingadipokinesbasecell typecomorbiditydiet-induced obesityfasting glucoseglucose metabolisminsulin secretionisletlipid metabolismlymph nodesmalemortalitynonhuman primatenovelnovel therapeutic interventionpandemic diseasepreclinical evaluationpreventrespiratoryresponsesingle cell analysissingle-cell RNA sequencingtranscriptomevariants of concernwestern diet
项目摘要
The COVID-19 global pandemic caused by the novel SARS-CoV-2 coronavirus continues to result in
significant morbidity and mortality worldwide. Although effective vaccines and therapeutics have been
introduced, COVID-19 will likely persist as a public health issue as a result of the risk of reinfection, the
emergence of variants of concern that may evade current vaccines, and the potential existence of latent viral
reservoirs. The risk for and the severity of COVID-19 are increased by a number of pre-existing conditions,
notably diabetes, cardiovascular disease, and hypertension. Conversely, there is increasing evidence of
altered glucose metabolism and new-onset diabetes as well as dyslipidemia in COVID-19 survivors,
suggesting that metabolic effects of COVID-19 may comprise an important component of post-acute sequelae
of COVID-19 (PASC). Thus, there is a bidirectional relationship between COVID-19 and metabolic disease, in
which concurrent metabolic disease constitutes an independent comorbid factor that increases COVID-19
severity on the one hand, while SARS-CoV-2 infection exerts deleterious effects through metabolically
important tissues to initiate new metabolic disease or accelerate the progression of pre-existing subclinical
metabolic disease on the other. Recent studies have shown that SARS-CoV-2 can infect pancreatic islets,
including b cells and other endocrine cell types, as well as adipocytes and white adipose tissue (WAT) immune
cells. Based on these data, we hypothesize that SARS-CoV-2 exerts direct and indirect effects on islet and
WAT function that result in the metabolic pathology associated with PACS We propose to address this
hypothesis through pursuit of the following specific aim.
Specific Aim1. Determine the effect of SARS-CoV-2 infection on the initiation and progression of metabolic
disease.
We will employ a now well-established rhesus macaque preclinical model of SARS-CoV-2 infection in which
lean, metabolically healthy and obese, insulin-resistant adult male rhesus macaques will be infected with the
delta variant of SARS-CoV-2 and followed for a 6-month time course, during which comprehensive longitudinal
assessments of viral load, lung pathology, immune cell profiles, and glucose and lipid metabolism will be
performed. Additionally, longitudinal samples of WAT immune cells and cross-sectional samples of infected
and non-infected islet cells with be analyzed by single-cell RNA-seq to characterize long-term alteration of
cellular profiles. At necropsy, islet function will be assessed and multiple tissue samples collected for
determination of viral distribution and persistence in potential latent reservoirs. The proposed studies represent
a unique opportunity to elucidate the mechanisms underlying the metabolic aspects of PASC in an
experimentally tractable preclinical model that permits assessments impossible in clinical studies.
由新型 SARS-CoV-2 冠状病毒引起的 COVID-19 全球大流行继续导致
全球发病率和死亡率显着。尽管已经有了有效的疫苗和治疗方法
据介绍,由于存在再次感染的风险,COVID-19 可能会持续作为一个公共卫生问题,
可能逃避当前疫苗的令人担忧的变体的出现,以及潜伏病毒的潜在存在
水库。许多既存疾病会增加 COVID-19 的风险和严重程度,
尤其是糖尿病、心血管疾病和高血压。相反,越来越多的证据表明
COVID-19幸存者的葡萄糖代谢改变和新发糖尿病以及血脂异常,
表明 COVID-19 的代谢影响可能是急性后遗症的重要组成部分
COVID-19 (PASC) 的。因此,COVID-19 与代谢疾病之间存在双向关系,
并发代谢疾病构成增加 COVID-19 的独立共病因素
一方面严重性,而 SARS-CoV-2 感染则通过代谢产生有害影响
引发新代谢疾病或加速已有亚临床疾病进展的重要组织
另一方面是代谢性疾病。最近的研究表明 SARS-CoV-2 可以感染胰岛,
包括 b 细胞和其他内分泌细胞类型,以及脂肪细胞和白色脂肪组织 (WAT) 免疫
细胞。根据这些数据,我们假设 SARS-CoV-2 对胰岛和胰岛产生直接和间接影响
WAT 功能导致与 PACS 相关的代谢病理学 我们建议解决这个问题
通过追求以下特定目标的假设。
具体目标 1.确定 SARS-CoV-2 感染对代谢启动和进展的影响
疾病。
我们将采用现已完善的 SARS-CoV-2 感染恒河猴临床前模型,其中
瘦弱、代谢健康和肥胖、胰岛素抵抗的成年雄性恒河猴将感染
SARS-CoV-2 的 delta 变体,并跟踪了 6 个月的时间过程,在此期间进行了全面的纵向研究
对病毒载量、肺部病理学、免疫细胞概况以及葡萄糖和脂质代谢的评估将
执行。此外,WAT 免疫细胞的纵向样本和感染病毒的横截面样本
和未感染的胰岛细胞,通过单细胞 RNA-seq 进行分析,以表征胰岛细胞的长期变化
蜂窝配置文件。在尸检时,将评估胰岛功能并收集多个组织样本用于
确定潜在潜伏病毒库中的病毒分布和持久性。拟议的研究代表
这是一个独特的机会来阐明 PASC 代谢方面的潜在机制
实验上易于处理的临床前模型,允许在临床研究中进行不可能的评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Kievit其他文献
Paul Kievit的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Kievit', 18)}}的其他基金
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease
肥胖对 SARS-COV-2 感染的影响以及 SARS-COV-2 对代谢疾病的相互影响
- 批准号:
10583175 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10468267 - 财政年份:2021
- 资助金额:
$ 128.66万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10326734 - 财政年份:2021
- 资助金额:
$ 128.66万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10624286 - 财政年份:2021
- 资助金额:
$ 128.66万 - 项目类别:
The impact of gastric bypass on maternal and offspring metabolic health
胃绕道手术对母婴代谢健康的影响
- 批准号:
10557865 - 财政年份:2020
- 资助金额:
$ 128.66万 - 项目类别:
The impact of gastric bypass on maternal and offspring metabolic health
胃绕道手术对母婴代谢健康的影响
- 批准号:
10355478 - 财政年份:2020
- 资助金额:
$ 128.66万 - 项目类别:
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
肥胖对 HIV 发病机制、抗逆转录病毒治疗和代谢合并症的影响
- 批准号:
10852482 - 财政年份:2019
- 资助金额:
$ 128.66万 - 项目类别:
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
肥胖对 HIV 发病机制、抗逆转录病毒治疗和代谢合并症的影响
- 批准号:
10015274 - 财政年份:2019
- 资助金额:
$ 128.66万 - 项目类别:
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
肥胖对 HIV 发病机制、抗逆转录病毒治疗和代谢合并症的影响
- 批准号:
10248477 - 财政年份:2019
- 资助金额:
$ 128.66万 - 项目类别:
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
肥胖对 HIV 发病机制、抗逆转录病毒治疗和代谢合并症的影响
- 批准号:
10657424 - 财政年份:2019
- 资助金额:
$ 128.66万 - 项目类别:
相似国自然基金
巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
- 批准号:82304503
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α7nAChR激动剂通过PGC-1α和HO-1调控肾小管上皮细胞线粒体的质和量进而改善脓毒症急性肾损伤的机制研究
- 批准号:82372172
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
- 批准号:82374256
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
- 批准号:82300771
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
- 批准号:82374209
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Mentoring Emerging Researchers at CHLA (MERCH-LA)
指导 CHLA (MERCH-LA) 的新兴研究人员
- 批准号:
10797938 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别:
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
- 批准号:
10639707 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别:
Natural model for evaluating within- and cross-species virus transmission
评估物种内和跨物种病毒传播的自然模型
- 批准号:
10735974 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别:
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease
优化用于预防和治疗 HSV 疾病的单克隆抗体的生成
- 批准号:
10717320 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别:
Adjuvant effect of physical exercise on immune response to COVID-19 vaccination and interactions with stress
体育锻炼对 COVID-19 疫苗接种免疫反应的辅助作用以及与压力的相互作用
- 批准号:
10593597 - 财政年份:2023
- 资助金额:
$ 128.66万 - 项目类别: